Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialEurope PMCOpen access

Intra-articular injection of umbilical cord-derived mesenchymal stem cells is safe and effective for moderate to severe knee osteoarthritis with synovitis: a double‑blinded and randomized controlled trial

Tong W., Shi Y., Wu D., Jia J., Xiang E., Xu D.

Randomized Controlled Trial with a reported sample of 55 on Knee Osteoarthritis, Osteoarthritis, published in BMC Musculoskelet Disord (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
BMC Musculoskelet Disord (2025)
Reported sample size
55
Source database
Europe PMC
PMID
41466394
PMCID
PMC12859901
DOI
10.1186/s12891-025-09440-y

Abstract (original English)

OBJECTIVES: To evaluate the safety and clinical efficacy of intra-articular injection of human umbilical cord–derived mesenchymal stem cells (UC-MSCs) for knee osteoarthritis (KOA). METHODS: This was a randomized, double-blind, placebo-control trial consisting of 3 arms including placebo, hyaluronic acid (HA), and UC-MSCs. 69 individuals were screened, with 55 participants subsequently randomized. The primary endpoint was the safety after injection. The secondary endpoints were improvements in visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Society Clinical Rating System (KSS), EuroQol five-dimensional questionnaire (EQ-5D), and magnetic resonance imaging (MRI) examinations at 6-month after injection. RESULTS: Adverse events (AEs) did not demonstrate significant differences among the groups. No serious treatment-related AEs were observed. Compared with placebo and HA, injection of UC-MSCs resulted in a greater improvement in VAS and EQ-5D; however, the differences were not statistically significant. Patients in the UC-MSCs group exhibited significant improvement in synovitis at the 6-month follow-up as compared with the placebo and HA groups (P = 0.003). At 6 months, UC-MSCs injection showed significantly better improvements in VAS (P = 0.011), WOMAC (P = 0.014), and EQ-5D scores (P = 0.049) in patients with KOA incorporat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Umbilical CordHumansOsteoarthritis, KneeSynovitisHyaluronic AcidMagnetic Resonance ImagingPain MeasurementTreatment OutcomeMesenchymal Stem Cell TransplantationInjections, Intra-Articular

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research